May 20, 2026

20 May 2026 — Sentante, a medical technology company focused on advancing endovascular interventions, today announced it has secured CE mark approval for its flagship device, marking a major transition from research and development to full commercial readiness.

The certification enables Sentante to begin marketing and selling its multi-domain robotic platform technology across European markets, following a period of intensive development and regulatory validation.

This milestone reflects the company’s progress over recent months in successfully navigating complex regulatory pathways, bringing its product from concept through to a clinically validated, market-ready solution.

“This is a defining moment for Sentante,” said Edvardas Satkauskas, CEO and co-founder of Sentante. “Achieving CE mark is not only a validation of our technology, but also of the rigorous work undertaken by our team to meet the highest regulatory standards. We are now positioned to move decisively into commercialisation and begin delivering real impact for clinicians and patients.”

Sentante’s device is designed to support endavascular procedures with enhanced precision and control, addressing critical needs in and redefining endovascular intervention procedures. With CE mark approval, the company can now partner with hospitals and healthcare providers across Europe to integrate the technology into routine clinical practice.

The approval follows a series of regulatory milestones achieved over the past months, underscoring the robustness of Sentante’s development programme and its commitment to safety, efficacy, and quality.

“Transitioning from an R&D-focused organisation to a commercial-stage company is a significant step,” added Dr. Tomas Baltrunas, co-founder of Sentante. “We have built the foundations not only to launch successfully, but to scale — ensuring that our innovation reaches the patients who need it most.”

Sentante will now focus on initial market rollout, clinician training, and expanding its commercial footprint, while continuing to advance its product pipeline.

Sentante recently unveiled its digital indeflator, a precision-controlled system that replaces the traditional manual indeflator used in endovascular procedures such as angioplasty and stent deployment.

About Sentante:

Sentante is a medical robotics company founded in 2017 building a haptic, device-agnostic endovascular platform that enables clinicians to perform complex vascular procedures remotely with full tactile feedback. Designed to integrate with existing cath-lab infrastructure, Sentante aims to expand access, improve clinician safety, and elevate procedural consistency across peripheral vascular, neurovascular and cardiovascular applications.

The driving force behind this breakthrough is a remarkably talented, multi-disciplinary team of engineers whose collective brilliance is matched only by their dedication. By seamlessly uniting world-class expertise across mechatronics, advanced electronics, and sophisticated software, these passionate problem-solvers have achieved a monumental feat: translating the exact, nuanced physics of human touch into the digital space.